CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from HC Wainwright

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $65.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 39.19% from the company's current price.

Other equities analysts have also issued reports about the stock. Needham & Company LLC reiterated a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a report on Thursday. Chardan Capital reissued a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Thursday. The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Barclays dropped their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. Finally, JMP Securities restated a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $69.53.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $46.70 on Friday. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $63.68. The stock has a market cap of $4.03 billion, a P/E ratio of -10.33 and a beta of 1.75. The stock has a 50 day simple moving average of $39.28 and a two-hundred day simple moving average of $40.56.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The firm's revenue was up 71.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.43) EPS. Sell-side analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now owns 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. SVB Wealth LLC bought a new position in CRISPR Therapeutics in the 1st quarter worth $25,000. Wood Tarver Financial Group LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $30,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the 1st quarter valued at about $27,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $36,000. Finally, Quantbot Technologies LP increased its holdings in CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock worth $45,000 after acquiring an additional 978 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.